Why Regeneron Is Quickly Becoming My Top Biotech Stock Pick


Approvals of new drugs with nine-figure sales potential and a full pipeline that can fuel future growth make this stock increasingly appealing at these prices. investors have lost a lot of money since 2015.



from Biotech News